News
RDY
14.19
+0.35%
0.05
Dr. Reddy’s Laboratories to Engage with Investors at Singapore Conference
TipRanks · 3d ago
Dr. Reddy's Laboratories to Attend Bank of America Investor Conference in Singapore
Reuters · 3d ago
Dr. Reddy's Laboratories' Aurigene Oncology Unit Results From 1st Two Groups Of Phase 1 Clinical Study Of AUR112 Demonstrates Safety, Meaningful Clinical Activity With Objective Responses Observed Across Multiple Lymphoma Subtypes
Benzinga · 4d ago
Dr. Reddy's Reports Promising Early Results for AUR112 in Lymphoid Malignancies
Reuters · 4d ago
AURIGENE ONCOLOGY LIMITED - AUR112 ACHIEVES 63.6% RESPONSE RATE IN PHASE 1 TRIAL
Reuters · 4d ago
AURIGENE ONCOLOGY LIMITED - AUR112 SHOWS SAFETY AND OBJECTIVE RESPONSES IN LYMPHOMAS
Reuters · 4d ago
AURIGENE ONCOLOGY LIMITED ANNOUNCES ENCOURAGING INITIAL DATA FROM 1ST TWO COHORTS OF PHASE 1 STUDY OF AUR112, AN ORAL SMALL MOLECULE INHIBITOR OF MALT1, IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES
Reuters · 4d ago
Dr. Reddy's Zytorvi Wins PBS Approval for Nasopharyngeal Cancer in Australia
Reuters · 4d ago
Weekly Report: what happened at RDY last week (1124-1128)?
Weekly Report · 5d ago
Dr. Reddy’s Laboratories to Engage with Investors at Tokyo Conference
TipRanks · 11/28 14:15
Aurigene Oncology, Dr. Reddy's Subsidiary, Hit with GST Penalty
Reuters · 11/28 11:04
Aurigene Oncology, Dr. Reddy's Subsidiary, Hit with Rs 64.9 Lakh Tax Penalty
Reuters · 11/28 11:04
BUZZ-U.S. STOCKS ON THE MOVE-Alibaba, Spotify, Alphabet
Reuters · 11/25 12:10
Dr. Reddy’s Gains EU Approval for Denosumab Biosimilar
TipRanks · 11/25 11:34
Is Zoetis Stock Underperforming the Dow?
Barchart · 11/25 07:51
Top pharmaceutical stocks by Quant to focus on as Novo Nordisk slides
Seeking Alpha · 11/24 17:10
Dr. Reddy's Laboratories Wins European Commission Approval for AVT03 Biosimilar
Reuters · 11/24 11:23
Alvotech SA Wins European Approval for AVT03, Biosimilar to Prolia and Xgeva
Reuters · 11/24 10:30
Weekly Report: what happened at RDY last week (1117-1121)?
Weekly Report · 11/24 10:17
Dr. Reddy's Laboratories Breaks Above 200-Day Moving Average - Bullish for RDY
NASDAQ · 11/19 16:08
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.